Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.00    2.50 (5.88%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £86.34m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

H1 2021 Update

15 Jul 2021 07:00

RNS Number : 2760F
Iofina PLC
15 July 2021
 

 

 

 

Iofina Plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

H1 2021 Update

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update to the market regarding its activities during the first half of 2021 ("H1" or the "Period").

 

Highlights

 

· Strong sales period with demand for Iofina iodine and halogen derivative products increasing as customer markets reopen

· Spot iodine prices have moved slightly higher to $35-37/kg, providing further increases in revenue

· H1 production of 249.4MT of crystalline iodine, in line with revised forecast of 250MT

· Expansion plans progressing well and IO#9 construction expected to begin by year end

 

The iodine market has continued its recovery, with prices now $35-37/kg, and the Company is seeing good demand for its iodine and halogen derivative products. Importantly, Iofina has been able to meet this demand and deliver strong H1 2021 sales, despite the interruption to the brine water supply at some plants in February. During H1 2021, 249.4 metric tonnes ("MT") of crystalline iodine was produced from Iofina's five operating IOsorb® plants, which was in line with the forecast cited in Company's Q1 2021 update.

 

For H2 2021, the Company is anticipating iodine production of 260-275MT, with operational changes at a brine partner's sites affecting supply levels to two of our plants this year. Despite this, Iofina believes it is currently on track to achieve full year revenue and profit targets.

 

The Company is working to increase brine supply and, given the recovery in the oil market, is anticipating some reinvestment in oil fields by its partners, which would boost brine output. The Company is also progressing well with expansion plans for IO#9 to further offset any reduced supply, with construction expected to commence by the end of the year.

 

 

Commenting, President and CEO of Iofina Dr. Tom Becker, stated: "The iodine market is seeing an excellent recovery in line with the rapidly accelerating global economic recovery as we begin to emerge from the challenging COVID-19 period. Demand is strong and prices are back at pre-pandemic levels of around $35-$37/kg, supporting higher revenue expectations. We are also seeing excellent recovery in the oil markets with prices up to around $75/bbl, which we are hopeful will result in increased reinvestment by our partners into their oil fields.

 

"I am also pleased with the progress being made towards IO#9 and we are expecting to begin construction of this new plant by the end of the year. This will not only reduce any risk from reduced brine supply seen by any of our plants but also ensure we are well positioned to meet the rising demand we are seeing globally for iodine and its derivative products.

 

"In spite of lower production, we are fulfilling demand with our capacity and we remain on track to meet full year expectations. The Company continues to meet its debt obligations and is in an excellent position to continue with our prudent growth strategy. I look forward to updating the market further on our expansion as well as provide a fuller update on the Period at our interim results."

 

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Tim Harper (Corporate Finance)

Tim Redfern (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Joe Burgess

Yellow Jersey PR Limited

Tel: +44 (0)20 3004 9512

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of Iodine and the manufacturing of specialty chemical products. As the second largest producer of iodine in North America, it comprises three USA entities; Iofina Resources, Iofina Chemical and IofinaEX.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products for over 35 years.

 

www.iofina.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFEEDDISLIL
Date   Source Headline
14th May 20197:00 amRNSStatement regarding share price rise
1st May 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSQ1 2019 Market Update
1st Apr 20197:00 amRNSCompletion of Debt Restructuring
22nd Feb 20194:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:35 pmRNSPrice Monitoring Extension
12th Feb 20197:00 amRNSDebt Restructuring
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
22nd Jan 20197:00 amRNSChange of Registered Office
17th Jan 20197:00 amRNSMarket Update
20th Nov 20184:40 pmRNSSecond Price Monitoring Extn
20th Nov 20184:35 pmRNSPrice Monitoring Extension
16th Nov 20187:00 amRNSDirector Appointment
18th Oct 20184:40 pmRNSSecond Price Monitoring Extn
18th Oct 20184:35 pmRNSPrice Monitoring Extension
10th Oct 20187:00 amRNSQ3 2018 Update
20th Sep 20187:00 amRNSInterim Results
16th Jul 20187:00 amRNSH1 2018 Update
18th Jun 20187:00 amRNSMarket update
14th Jun 20187:00 amRNSGrant of Options
13th Jun 201811:30 amRNSResult of AGM
30th Apr 20187:00 amRNSFinal Results and Notice of AGM
18th Apr 20187:00 amRNSQ1 2018 Market Update
16th Apr 20181:30 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
20th Mar 20183:05 pmRNSHolding(s) in Company
15th Mar 20181:24 pmRNSHolding(s) in Company
14th Feb 20187:00 amRNSProduction commences at IO#7
30th Jan 20183:00 pmRNSHolding(s) in Company
15th Jan 20187:00 amRNSMarket Update
14th Dec 20177:00 amRNSMarket Update
16th Nov 20177:00 amRNSIO#7 Progress and Market Update
20th Oct 20174:40 pmRNSSecond Price Monitoring Extn
20th Oct 20174:35 pmRNSPrice Monitoring Extension
10th Oct 20177:00 amRNSQ3 2017 Market Update
22nd Sep 20177:00 amRNSInterim Results
12th Sep 20177:00 amRNSConstruction of IO#7 to Expand Iodine Production
14th Jul 20177:00 amRNSCorporate and Production Update
14th Jun 201712:15 pmRNSResult of AGM
13th Jun 201712:07 pmRNSSecond Price Monitoring Extn
13th Jun 201712:02 pmRNSPrice Monitoring Extension
8th Jun 201712:07 pmRNSSecond Price Monitoring Extn
8th Jun 201712:02 pmRNSPrice Monitoring Extension
7th Jun 201712:07 pmRNSSecond Price Monitoring Extn
7th Jun 201712:02 pmRNSPrice Monitoring Extension
6th Jun 201712:07 pmRNSSecond Price Monitoring Extn
6th Jun 201712:02 pmRNSPrice Monitoring Extension
24th May 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.